Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech Half-Year Review 2014


EP Vantage Pharma & Biotech Half-Year Review 2014

 Download EP Vantage Pharma & Biotech Half-Year Review 2014

The latest report from EP Vantage reviews the performance of the pharma & biotech industry in the first half of 2014 and reveals that while an M&A frenzy accounting for nearly $90 billion of equity set the pace for the first half of 2014, a slowdown in IPOs and six months of volatile market activity could tarnish the year’s shimmering start.

Key highlights in EP Vantage's Pharma & Biotech Half-Year Review 2014 include:

  • IPOs peaked in the first quarter at $2.1 billion, but fell back to $913 million to end the first half of the year
  • Companies raised more than $3 billion in venture capital in the first six months, putting the sector on pace to exceed the $5.9 billion raised in 2007
  • The first seven months of 2014 saw the FDA approve 27 novel agents, which are forecast to generate $7 billion in US sales over the next five years

Download Report

Download EP Vantage Medtech Half Year Review 2014

Press Release

Related Reports: 

EP Vantage Medtech 2013 in Review

EP Vantage Pharma and Biotech 2013 in Review

EP Vantage: A Breakthrough Year for Unmet Diseases

EP Vantage FDA Approval Rates 2013